

PROPOSED ACQUISITION OF SHARES IN SMG INTERNATIONAL (VIETNAM) PTE. LTD.
- RECEIPT OF LISTING AND QUOTATION NOTICE IN RESPECT OF THE CONSIDERATION SHARES

1. INTRODUCTION

The Board of Directors (the "**Board**") of Singapore Medical Group Limited (the "**Company**") refers to the announcement dated 19 August 2021 (the "**Earlier Announcement**") in relation to the proposed acquisition of 850,000 issued and fully paid ordinary shares representing the remaining 50% of the issued and paid up share capital in SMG International (Vietnam) Pte. Ltd. (the "**Proposed Acquisition**"), under which 3,398,203 new ordinary shares in the share capital of the Company (the "**Consideration Shares**") are to be issued and allotted to certain Vendors as part of the consideration payable under the Proposed Acquisition.

All capitalised terms used and not defined herein shall have the same meanings given to them in the Earlier Announcement.

2. RECEIPT OF LISTING AND QUOTATION NOTICE

Further to the Earlier Announcement, the Board is pleased to announce that the Company has, on 31 August 2021, received the listing and quotation notice ("**LQN**") from the SGX-ST for the listing and quotation of the Consideration Shares on the Catalist, subject to compliance with the SGX-ST's listing requirements.

The LQN is not to be taken as an indication of the merits of the Proposed Acquisition, the Consideration Shares, the Company, its subsidiaries and their securities.

The Company will make the necessary announcement(s) on the Proposed Acquisition as appropriate or when there are further developments on the same.

By Order of the Board

Beng Teck Liang
Executive Director and Chief Executive Officer
1 September 2021

*This announcement has been prepared by Singapore Medical Group Limited (the "**Company**") and its contents have been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "**Sponsor**") for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist.*

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881.